Original Article

Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test

Mariangela F Silveira a,*, Marilia A Mesenburg a,b, Odir A Dellagostin a, Natasha R de Oliveira a, Mara AC Maia a, Francisco D Santos a, André Vale c, Ana M B Menezes d, Gabriel D Victora e, Cesar G Victora a, the EPICOV19 Group Aluisio JD Barros a, Luis Paulo Vidaletti a, Fernando P Hartwig a, Fernando C Barros d, Pedro C Hallal a, Bernardo L Horta a

a Universidade Federal de Pelotas, Pelotas, RS, Brazil
b Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
c Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
d Universidade Católica de Pelotas, Pelotas, RS, Brazil
e Laboratory of Lymphocyte Dynamics, Rockefeller University, New York, United States

ABSTRACT

Background: Large-scale epidemiological studies of seroprevalence of antibodies against SARS-CoV-2 often rely on point-of-care tests that provide immediate results to participants. Yet, little is known on how long rapid tests remain positive after the COVID-19 episode, or how much variability exists across different brands and even among batches of the same test.

Methods: In November 2020, we assessed the sensitivity of three tests applied to 133 individuals with a previous positive PCR result between April and October. All subjects provided finger prick blood samples for two batches (A and B) of the Wondfo lateral-flow IgG/IgM test, and dried blood spot samples for the S-UFRJ ELISA test.

Results: Overall sensitivity levels were 92.5% (95% CI 86.6–96.3), 63.2% (95% CI 54.4–71.4) and 33.8% (95% CI 25.9–42.5) for the S-UFRJ test, Wondfo A and Wondfo B tests, respectively. There was no evidence of a decline in the positivity of S-UFRJ with time since the diagnosis, but the two Wondfo batches showed sharp reductions to as low as 41.9% and 19.4%.

Keywords: SARS-CoV-2, Rapid test, ELISA, PCR, Validation, Epidemiological serosurvey

Authors' contributions. OAD, NRO, MACM, FDS and AV were in charge of the laboratory analyses. LPV, AJDB, BLH and CGV analyzed the data. MFS, AMBM and MM were in charge of data collection. MFS, MM, GDV and CGV prepared the manuscript. PCH acted as the overall coordinator of the project. FCB contributed with the literature search. All authors reviewed and approved the final version of the manuscript.

* Corresponding author.

E-mail addresses: mariangelafreitassilveira@gmail.com (M.F. Silveira), mariliaepei@gmail.com (M.A. Mesenburg), odird@gmail.com (O.A. Dellagostin), oliveira_natasha@hotmail.com (N.R. de Oliveira), maracamaia@hotmail.com (M.A. Maia), denis.santos195@gmail.com (F.D. Santos), valeimuno@gmail.com (A. Vale), anamene.epi@gmail.com (A.M.B. Menezes), victora@rockefeller.edu (G.D. Victora), cvictora@gmail.com (C.G. Victora).

https://doi.org/10.1016/j.bjid.2021.101601
1413-8670/© 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Serological tests are critical in the context of infectious disease outbreaks because they have the potential to identify the true prevalence of infection in a population, allowing measures such as the infection fatality rate to be accurately calculated. This property is based on the assumption, however, that serum antibodies remain detectable for long periods after an infectious agent is eliminated from the host. While well-grounded on our collective experience with other viral infections, the validity of this assumption in the case of SARS-CoV-2 is less clear. A number of studies, including one from our own group, have shown declines over time in SARS-CoV2 antibody titers or percent positivity using various assays, either at the individual or population levels, although other studies reported stable antibody levels. Comparison of these results is confounded by the use of different antibody assays, including rapid lateral flow tests, ELISAs, and commercial chemiluminescence tests, all of which have different and often poorly-defined cut-off points for determining seropositivity.

The first COVID-19 cases in Brazil were reported in February 2020. In the State of Rio Grande do Sul, the first case was confirmed on March 10, and a series of regular population-based antibody surveys was started on April 11 in nine cities. In early May, the study was expanded to include 133 large cities in Brazil’s 27 federation units, covering an area of approximately 4200 by 4000 km; so far four data collection rounds were completed, with over 25,000 individuals having been tested in each phase. At the time the studies were launched, the only antibody test available in large numbers in Brazil was a rapid lateral-flow test (Wondfo SARS-CoV-2 Antibody Test, Wondfo Biotech Co., Guangzhou, China), which had been purchased by a large company and donated to the Ministry of Health. The first three rounds of the national study, carried out in May and June, showed a steady increase in uncorrected prevalence from 1.9% to 3.8% (95% CI 3.5–4.1) over a five-week period. For the fourth round, carried out in August 2020, the research team no longer had access to the original batch of tests, and it was necessary to purchase 50,000 units from the sole Brazilian company that imported the Wondfo test. Results from the fourth phase showed a surprisingly low prevalence of antibodies, of only 1.4% (95% CI 1.2–1.6), at a time when the numbers of reported cases and deaths had been steadily increasing in most of the country.

Although at the time of the fourth round of the national survey, there was already evidence from the literature that antibody titers in large-scale studies had been falling over time according to some studies, the marked reduction observed in our survey was unexpected. As a consequence, we launched a study to compare how the sensitivity of the two batches of the Wondfo test vary with time since PCR-confirmed diagnosis of COVID-19. We also took the opportunity to assess the validity of a new low-cost ELISA test developed in Brazil that relies on dried blood spots collected on filter paper that may represent a practical and affordable alternative for large-scale epidemiological studies.

Material and methods

Following ethical approval by the Brazilian National Ethics Committee (process number 30415520.2.0000.5313), local health authorities, hospitals and laboratories in the city of Pelotas, Brazil, were requested to allow access to lists of patients with positive PCR tests for SARS-CoV-2 from March to October 2020. Patients were contacted by phone, and starting from these contacts, snowball sampling was used to obtain a larger number of subjects who had tested positive. All participants signed informed consent forms before providing samples.

Data collection was conducted in October and November 2020. Subjects were visited at home, at least 14 days after the original PCR result. A trained team of health visitors, wearing personal protection equipment, obtained blood samples by fingerpick draw. Three tests were performed on each subject: an in-house direct ELISA to detect IgG to the SARS-CoV-2 spike (S) protein from dried blood spot samples (S-UFJR ELISA) and two different batches of the Wondfo SARS-CoV-2 Antibody Test, which detects antibodies to the S-protein’s receptor binding domain (RBD).

First, three drops of blood were collected on three replicate filter paper pads attached to a plastic strip and allowed to dry. Samples were sent to the Biotechnology Laboratory at the Federal University of Pelotas for ELISA testing. Eluates were assayed using the S-UFJR ELISA protocol as described previously. The S-UFJR ELISA displayed 98.4% specificity and...
Briefly, high-binding ELISA plates (Corning) were coated with 50 μL of SARS-CoV-2 S protein at 4 μg/mL suspended in PBS and incubated overnight. The coating solution was removed and 250 μL of PBS 1% BSA (blocking solution) was added to the plate and incubated at room temperature for 1–2 h. Meanwhile, single filter paper pads cut from the plastic strips were used to prepare eluates by incubating for one hour at room temperature in 200 μL of PBS 1% BSA. The blocking solution was then removed and 50 μL of eluate was added to the plate and incubated at room temperature for two hours. The plate was then washed five times with 250 μL of PBS. Next, 50 μL of 1:10,000 goat anti-human IgG (Fc)-horseradish peroxidase antibody (Rhea Biotech) was added to the plate and incubated for 1.5 h at room temperature. The plate was then washed five times with 250 μL of PBS. Finally, TMB (3,3′, 5,5′-tetramethylbenzidine) (Thermo Fischer) horseradish peroxidase substrate was added, and the reaction allowed to develop for 15 min; the reaction was stopped with 50 μL of 1 N HCl, and optical density (OD) was read at 450 nm with 655 nm background compensation in a microplate reader (Biochrom EZ read 400). Relative levels of antibodies are expressed as OD ratio of values of individual samples to the mean plus three standard deviations of the OD average of the negative controls in the same ELISA plate. An OD ratio below 0.9 indicates a negative result, an OD ratio above 1.1 indicates a positive result, and an OD ratio between 0.9 and 1.1 is considered undetermined, which is compatible with the range used in most commercial diagnostic ELISA tests. Because samples were assayed at a single dilution, data were plotted as a dichotomous rather than a quantitative variable, although the test also allows quantification of antibody titers using multiple dilutions.

After collection of filter paper samples, each subject provided additional drops of blood for two different batches of the Wondfo SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). Batch A was part of 500,000 kits imported in March 2020 directly from China by the Brazilian Ministry of Health, with funding from Vale do Rio Doce, a private mining company (batch numbers W19500433, W19500450, W19500498 and W19500460). Batch B (number W195004116) was part of a lot of 50,000 kits purchased by the Federal University of Pelotas directly from the Wondfo representatives in Brazil. The use-by dates of the two batches were October 2020–April 2021, and April 2021, respectively.

This is a rapid point-of-care lateral-flow test that detects IgG and/or IgM isotypes specific to the RBD portion of the SARS-CoV-2 S protein. Test results were read after 15 min by the field worker and the kits were photographed for a second independent reading by a supervisor (MFS). According to the manufacturer, the test’s sensitivity and specificity are 86.4% (95% CI 82.4–89.6) and 99.6% (95% CI 97.6–99.9), respectively. By pooling the results from four available validation studies, one of which was carried out by our team before the first survey round, we estimated a sensitivity level of 84.8% (95% CI 81.4–87.8). Specificity was estimated at 99.95% based on an early survey we carried out in a population-based sample of 4188 subjects at an early stage of the epidemic in Rio Grande do Sul state; we considered that the two individuals with positive results were false positives.

All subjects were classified according to the calendar month when the positive PCR tests had been carried out. Results of the three different tests were tabulated according to the month of the PCR.

**Results**

We tested 133 subjects with positive PCR results from March to October 2020. There were no refusals. Because there were few cases in the city during the first half of the year, the five cases diagnosed from March to May were pooled with the 26 cases from June. The numbers of cases by month are shown in Table 1. Of the 133 subjects, 77 were women and the mean age was 41.7 years and the standard deviation 15.9 years (range 3 to 88 years).

Of the 133 ELISA tests, 123 were positive, seven inconclusive and three negative. For further analyses, inconclusive tests were recorded as negative. For Wondfo A tests, 84 were positive, and 45 for Wondfo B.

Sensitivity results, using PCR as the gold standard, are shown in Table 1 and graphically in Fig. 1. Overall sensitivity was 92.5% for ELISA, 63.2% for Wondfo batch A, and 33.8% for Wondfo batch B. Whereas sensitivity of the ELISA test remained stable at around 90%, with no evidence of a decline, both Wondfo tests showed marked reductions in sensitivity over time. The confidence intervals for the three tests (Table 1) are rather wide due to the study’s sample size. Nevertheless, none of the 95% CI’s for the Wondfo B test overlap with those from the ELISA test.

Compared to the ELISA test, sensitivity of Wondfo A was 66.7% (82/123) and of Wondfo B 36.6% (45/123). Using Wondfo A as the gold standard, the sensitivity of Wondfo B was equal to 47.6% (40/84), ranging from 65.0% in October to 46.2% in July. Chi-squared tests for linear time trends in proportions showed P levels of 0.802 for ELISA, 0.001 for Wondfo A and 0.011 for Wondfo B.

| Month | Subjects | Sensitivity | 95% CI | Sensitivity | 95% CI | Sensitivity | 95% CI |
|-------|----------|-------------|-------|-------------|-------|-------------|-------|
| Jun   | 31       | 87.1%       | 70.2% | 96.4%       |       | 41.9%       | 24.5% | 60.9%       |       | 19.4%       | 7.5%  | 37.5%       |       |
| Jul   | 26       | 100.0%      | 86.8% | 100.0%      |       | 61.5%       | 40.6% | 79.8%       |       | 30.8%       | 14.3% | 51.8%       |       |
| Aug   | 25       | 92.0%       | 74.0% | 99.0%       |       | 56.0%       | 34.9% | 75.6%       |       | 32.0%       | 14.9% | 53.5%       |       |
| Sep   | 26       | 92.3%       | 74.9% | 99.1%       |       | 80.8%       | 60.6% | 93.4%       |       | 38.5%       | 20.2% | 59.4%       |       |
| Oct   | 25       | 88.5%       | 74.0% | 99.0%       |       | 80.0%       | 59.3% | 93.2%       |       | 52.0%       | 31.3% | 72.2%       |       |
| All   | 133      | 92.5%       | 86.6% | 96.3%       |       | 63.2%       | 54.4% | 71.4%       |       | 33.8%       | 25.9% | 42.5%       |       |

**Table 1 – Sensitivity of the three tests for COVID-19 according to date of the original PCR result.**

We tested 133 subjects with positive PCR results from March to October 2020. There were no refusals. Because there were few cases in the city during the first half of the year, the five cases diagnosed from March to May were pooled with the 26 cases from June. The numbers of cases by month are shown in Table 1. Of the 133 subjects, 77 were women and the mean age was 41.7 years and the standard deviation 15.9 years (range 3 to 88 years).

Of the 133 ELISA tests, 123 were positive, seven inconclusive and three negative. For further analyses, inconclusive tests were recorded as negative. For Wondfo A tests, 84 were positive, and 45 for Wondfo B.

Sensitivity results, using PCR as the gold standard, are shown in Table 1 and graphically in Fig. 1. Overall sensitivity was 92.5% for ELISA, 63.2% for Wondfo batch A, and 33.8% for Wondfo batch B. Whereas sensitivity of the ELISA test remained stable at around 90%, with no evidence of a decline, both Wondfo tests showed marked reductions in sensitivity over time. The confidence intervals for the three tests (Table 1) are rather wide due to the study’s sample size. Nevertheless, none of the 95% CI’s for the Wondfo B test overlap with those from the ELISA test.

Compared to the ELISA test, sensitivity of Wondfo A was 66.7% (82/123) and of Wondfo B 36.6% (45/123). Using Wondfo A as the gold standard, the sensitivity of Wondfo B was equal to 47.6% (40/84), ranging from 65.0% in October to 46.2% in July. Chi-squared tests for linear time trends in proportions showed P levels of 0.802 for ELISA, 0.001 for Wondfo A and 0.011 for Wondfo B.
Table 2 shows that there was little variation in the sensitivity of the ELISA and Wondfo B tests by age and sex of the subject, but sensitivity of the Wondfo A test appeared to be lower in women ($P=0.062$) and in individuals aged 40–49 years ($P=0.072$).

**Discussion**

We have used the Wondfo test in repeated population-based surveys carried since April 2020, when it was the only test available at large scale in Brazil. Its advantages included producing results within 15 min, thus allowing field work to be completed within four days in 133 cities with a sample size of over 30,000 subjects. Our choice was supported by early validation studies – including our own – showing a level of sensitivity around 80%, with very high specificity. A comparison of 12 rapid tests carried out at the University of California San Francisco showed that the Wondfo test used in our study was among the ones with the best performance, with sensitivity over 80% and specificity over 99%. In the present analyses, we also found sensitivity levels of around 80% in recently diagnosed COVID-19 cases (Fig. 1), using the same batch of the Wondfo test we used in April during the original validation.

At the early stage in the pandemic, it was widely assumed that seropositive individuals would remain so for many months, as had been observed during the original SARS-1 epidemic, but not all studies started to report rapid drops in antibody levels. Within the first three rounds of our nationwide survey (May-June), we had already noticed substantial drops over time in high-prevalence Amazon cities which were the most affected early in the pandemic. An even more dramatic drop was noted in August, when 1.4% of individuals tested positive compared to 3.8% in June. This observation prompted the present analyses.

The validation analyses confirmed our suspicion of a systematic difference between two sets of batches. Compared to the gold standard PCR results, sensitivity of the first and second batches were equal to 63.2% and 33.8%, respectively, with both batches showing rapid declines over time. Earlier studies comparing the performance of different brands of rapid tests had shown substantial variability, but to our knowledge this...
is the first evidence of marked differences among different batches of the same test brand, not only for recently diagnosed patients but also over time. Batch-related issues may have contributed to the discrepancies between studies measuring the sensitivity of the Wondfo test in different settings. Further batch-by-batch validation studies of similar laterality, point-of-care tests are warranted.

In light of the recent development of the S-UFRJ ELISA test in Brazil, we took the opportunity to also assess its sensitivity in the same study. Unlike the rapid tests, ELISA showed high sensitivity of 92.5% overall, and no evidence of a decline over the five months of the study. The ELISA test has very low cost (about US$1.00 per test including lab costs) and is performed on dried blood spots. These characteristics suggest that this test, and possibly other similar ELISA tests, may be advantageous over point-of-care tests in large epidemiological studies. For comparison purposes, the price paid for the each Wondfo B test in Brazil was around US$5.00.

Although the reasons for the discrepancy between the Wondfo and S-UFRJ test are unclear, two factors may play a role. First, the Wondfo test detects both IgM and IgG antibodies, the first of which decay more rapidly with time post-infection.10,33,34 If positivity in the Wondfo test is driven primarily by high-avidity IgM interactions, loss of positivity with time is to be expected. Second, a recent report10 indicates that antibodies specific to the RBD, detected by the Wondfo test, decay more rapidly than those binding to other regions of the S protein, the antigen of S-UFRJ. Thus, measuring anti-RBD antibodies, while advantageous when attempting to assess neutralization potential, may not be ideal for assessments of antibody prevalence in a population.

Our findings cast serious doubts about the use of this brand of rapid antibody tests for epidemiological studies. We are now using the curves of test positivity by time since the initial PCR to correct the observed antibody prevalence in each phase of Rio Grande do Sul and Brazil studies. The correction factor considers declining positivity over time, as well as the epidemic curve (based on reported deaths and cases) in each city. Further batch-by-batch validation studies of similar laterality, point-of-care tests are warranted.

Role of the funding sources. The funding sources did not have any role in the analyses or preparation of the manuscript.

Conflicts of interest

None.

Acknowledgment

We acknowledge Leda R. Castilho, Renata G. F. Alvim, and Tulio M. Lima from Cell Culture Engineering Lab at COPPE/UFRJ for providing the purified Spike protein used in the S-UFRJ ELISA, and “Todos Pela Saúde” initiative, Instituto Serra-Pilheira, Brazilian Ministry of Health, Brazilian Collective Health Association (ABRASCO) and the JBS S.A. initiative ‘Fazer o Bem Faz Bem’.

References

1. Putz MM, Alberini I, Midgley CM, Manini I, Montomoli E, Smith GL. Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol. 2005;86(11):2955–60.
2. Wu L-P, Wang N-C, Chang Y-H, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–4.
3. Antia A, Ahmed H, Handel A, et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 2018;16(8):e2006601-e.
4. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet North Am Ed.
5. Ministerio de Ciencia e Innovacion and Ministerio de Salud. Spain. Estudio ENE-Covid-19: Informe Final Estudio Nacional de Sero-Epidemiologia de la Infección por SARS-CoV-2 en España. Madrid, España.
6. Röltgen K, Wiz R, Stevens BA, et al. SARS-CoV-2 antibody responses correlate with resolution of RNAemia but are short-lived in patients with mild illness. medRxiv. 2020.
7. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–7.
8. Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv. 2020. 2020.07.09.20148429.
9. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4. https://doi.org/10.1038/s41591-020-0965-6.
10. Reibel C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. bioRxiv. 2020.
11. Chen Y, Tong X, Li Y, et al. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020;16(9):e1008796.
12. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J Infect Dis. 2020;223(2):197–205. https://doi.org/10.1093/infdis/jiaa618.
13. Dulipsingh L, Ibrahim D, Schaefer EJ, et al. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma. Transfus Apheresis Sci. 2020;59(6):102922.
14. Kaufman HW, Chen Z, Meyer 3rd WA, Wohlgemuth JC. Insights from patterns of SARS-CoV-2 immunoglobulin G serology test results from a national clinical laboratory, United States, march-July 2020. Popul Health Manag. 2020;24(5):S35–42. https://doi.org/10.1093/pop.2020.0256.
15. Lei Q, Li Y, Hou HY, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2020;76(2):551–61. https://doi.org/10.1111/all.14622.
16. Liu C, Dun Y, Liu P, et al. Associations of medications used during hospitalization and immunological changes in patients with COVID-19 during 3-month follow-up. Int Immunopharmacol. 2020;89(Pt A):107121.

17. Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott architect. J Clin Virol. 2020;133:104663.

18. Nag DS, Chaudhry R, Mishra M, Rai S, Gupta M. A Prospective study on rapidly declining SARS-CoV-2 IgG antibodies within one to three months of testing IgG positive: can it lead to potential reinfections? Cureus. 2020;12(12):e11845.

19. Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network - 12 states, April-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(47):1762–6.

20. Wang Y, Li J, Li H, Lei P, Shen G, Yang C. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol. 2020;90:107271.

21. Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2020;184(1):169–83. https://doi.org/10.1016/j.cell.2020.11.029.

22. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382:2302–15. https://doi.org/10.1056/NEJMoa2006100.

23. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020:eabd7728.

24. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2020. 2020.11.15.383323.

25. Silveira MF, Barros AJD, Horta BL, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. Nat Med. 2020;26(8):1196–9.

26. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Health. 2020;8(11):e1390–e8.

27. Alvim RGF, Lima TM, Rodrigues DAS, et al. An affordable anti-SARS-CoV-2 spike protein ELISA test for early detection of IgG seroconversion suited for large-scale surveillance studies in low-income countries. medRxiv. 2020. 2020.07.13.20152884.

28. Pellanda LC, Wendland EM, McBride AJA, et al. Sensitivity and specificity of a rapid test for assessment of exposure to SARS-CoV-2 in a community-based setting in Brazil. medRxiv. 2020. 2020.05.06.20093476.

29. Whitman JD, Hiatt J, Mowery CT, et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol. 2020;38(10):1174–83.

30. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249–51.

31. Cao WC, Liu W, Zhang PH, Zhang F, Richards JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2020;375(11):1162–3.

32. Chang SC, Wang JT, Huang LM, et al. Longitudinal analysis of severe acute respiratory syndrome (SARS) coronavirus-specific antibody in SARS patients. Clin Diagn Lab Immunol. 2005;12(12):1455–7.

33. Borremans B, Gamble A, Prager KC, et al. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. eLife. 2020;9:e60122. https://doi.org/10.7554/elife.60122.

34. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. https://doi.org/10.1126/sciimmunol.abe5511.